Figure 1

Generation of hTAP-LMP transgenic mice.

(A) Schematic map of the BAC clone RP11-10A19. (B) PCR genotyping of the founder mice. F2 and F14 were the two positive founder mice. “−”, tail DNA samples of WT littermates; “+”, plasmid DNA of the BAC clone RP11-10A19. (C) Relative mRNA expression of human TAP1, TAP2, PSMB8 and PSMB9 in splenocytes from WT or hTAP-LMP mice as analyzed by qRT-PCR and normalized to 18S rRNA levels. (D) Expression of human TAP1 (65 kDa), TAP2 (75 kDa), PSMB8 (23/28 kDa) and PSMB9 (22 kDa) in WT or hTAP-LMP mice was determined by western blotting; β-actin (42 kDa) was used as an internal control. (E) FACS analysis for CD4 and CD8 expression of splenocytes from WT and hTAP-LMP mice (up), with the percentage of CD4⁺ T cells (below, left) and CD8⁺ T cells (below, right). PCR genotyping and western blotting were performed on individual mice and the depicted results are representative of at least three independent experiments. Full-length PCR gels and Western blots are presented in Supplementary Figs S6 and S7, respectively. Results of the qRT-PCR and FACS analysis are representative of at least three independent experiments with n ≥ 3. Data represent the mean ± SD. ns, not significant.